Myriad Genetics clears analyst hurdle, shares steady on NASDAQ

Myriad Genetics Inc on NASDAQ draws fresh attention after a recent analyst move and a steady share price, as investors track the diagnostics group in the wider US healthcare sector.

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 22:32.

Myriad Genetics Inc (US62855J1043) remains in focus on the NASDAQ today with a stable share profile, while investors digest recent analyst commentary on the US diagnostics group. The stock trades in the broader S&P 400 mid-cap universe, providing a recognizable anchor for international portfolios.

What recent reports highlight

Myriad Genetics Inc, headquartered in Salt Lake City, focuses on molecular diagnostics and has attracted coverage from several US healthcare analysts in recent weeks, referencing its hereditary cancer and pharmacogenomics testing portfolio. A recent note summarized on an analyst aggregation platform points to a mixed stance, with ratings spread between Buy and Hold, highlighting execution risk in a competitive market. MarketScreener consensus overview for Myriad Genetics

MarketScreener data shows that a mid-single-digit number of analysts currently follow Myriad Genetics, with an average 12-month price target above the present trading level, indicating some upside potential in the eyes of the sell-side but with caution around profitability. The company remains part of the US healthcare diagnostics peer group that includes names such as Exact Sciences and Natera, where valuation multiples and growth expectations are closely monitored by institutional investors.

How analysts frame the stock

In a recent sector commentary on US diagnostics, one broker report cited Myriad Genetics as a restructuring story, referencing prior efforts to streamline its product portfolio and cost base to improve margins. The note pointed out that Myriad’s revenue mix is shifting toward more precise, clinically actionable tests in oncology and women’s health, a trend seen as positive but requiring sustained investment. Benzinga market commentary on Myriad Genetics

Analyst consensus data from sites like MarketScreener and TipRanks indicates that Myriad Genetics sits in the middle of its peer group on valuation metrics such as price-to-sales, reflecting both its established franchise and lingering questions about long-term growth. Several notes emphasize the importance of upcoming quarters for confirming that the company can translate its test menu into sustainable cash generation, especially as payers and regulators push for cost-effectiveness in diagnostics.

The product behind the stock

Myriad Genetics generates revenue primarily through clinical genetic tests ordered by physicians, with flagship offerings including hereditary cancer panels under the MyRisk brand and prenatal testing solutions. These tests analyze patient DNA to identify variants associated with increased disease risk or potential drug-response issues, helping guide treatment decisions in oncology and women’s health. MyRisk hereditary cancer test information on Myriad

Where the stock trades today

As of 2026-06-25, 20:20, Myriad Genetics Inc shares trade on the NASDAQ at around 18.50 USD, keeping a relatively tight range in recent sessions compared with more volatile peers in the US diagnostics segment.

Myriad Genetics Inc at a glance

• Company: Myriad Genetics Inc
• ISIN: US62855J1043
• WKN: 914617
• Ticker: MYGN
• Trading venue: NASDAQ
• Price (as of 2026-06-25, 20:20): 18.50 USD
• Market cap: approximately 1.3 billion USD (as of 2026-06-25)
• Sector / industry: Healthcare - Biotechnology / Diagnostics
• Index membership: S&P 400 MidCap (healthcare segment)
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.